Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7836748 in Advanced Solid Tumors With a RAS G12V Mutation
NCT07905924Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2026
- Primary completion
- Mar 2032
01
Overview
Phase 1, randomised, open-label trial of RO7836748 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 1 more (6 arms), sponsored by Roche. Primary endpoints: Incidence and Severity of Adverse Events up to 5 years, Incidence of Dose-limiting Toxicities at 28 days and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
RO7836748
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07905924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905924.